TGF-β1 Reverses Inhibition of COX-2 With NS398 and Increases Invasion in Prostate Cancer Cells

被引:6
|
作者
Ding, Qiang [1 ]
Bai, Yu-Feng [1 ]
Wang, Yong-Quan [1 ]
An, Rui-Hua [1 ]
机构
[1] Harbin Med Coll, Dept Urol, Clin Coll 1, Harbin 150001, Peoples R China
来源
AMERICAN JOURNAL OF THE MEDICAL SCIENCES | 2010年 / 339卷 / 05期
关键词
Prostate cancer; Cyclooxygenase-2; Growth factors; Prostaglandin-E2; Inhibitor; COLORECTAL-CARCINOMA CELLS; CYCLOOXYGENASE-2; EXPRESSION; MOLECULAR PATHOLOGY; SIGNALING PATHWAYS; STROMA INTERACTION; PROSTAGLANDIN E-2; BONE; DISEASE; GROWTH; PROLIFERATION;
D O I
10.1097/MAJ.0b013e3181d7c9db
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone-derived transforming growth factor (TGF)-beta 1 leads to tumor growth, osteoblastic lesions and more invasion. Degradation of basement membranes caused by cyclooxygenase (COX)-2 is known as a distinctive feature of invasive cells. We investigated inhibition of COX-2 with NS398 in PC-3 and LNCaP cell lines. TGF-beta 1 and dmPGE2 were added in NS398 treated or untreated cells. COX-2 did not express in PC-3, after treatment with TGF-beta 1, COX-2 appeared and accompanied with enhanced invasion. COX-2 expressed in LNCaP, undetectable after addition of NS398 along with decreased invasion. Addition of TGF-beta 1 reversed inhibition of NS398 in both cell lines. DmPGE2 augmented invasion in both cell lines without alteration of COX-2. These results suggest that TGF-beta 1 can increase invasion and reverse inhibition of COX-2 induced by NS398. We indicate that bone-derived TGF-beta 1 might contribute to clinical unsatisfied effect of NSAIDs or COX-2 specific inhibitors adjuvant therapies. Our data provide a new potential therapy for fighting against prostate cancer.
引用
收藏
页码:425 / 432
页数:8
相关论文
共 50 条
  • [21] The COX-2 inhibitor NS-398 causes T-cell developmental disruptions independent of COX-2 enzyme inhibition
    Xu, H
    Izon, DJ
    Loftin, C
    Spain, LM
    CELLULAR IMMUNOLOGY, 2001, 214 (02) : 184 - 193
  • [22] Impairment of breast cancer cell invasion by COX-2-specific inhibitor NS398: roles of CXCR4 and of uPA system
    Silva, Henriqueta Coimbra
    Alves, Vera
    Mesquita Nogueira, Luis Alcides
    Rosa, Manuel Santos
    Carvalho, Lina
    Regateiro, Fernando
    MEDICAL ONCOLOGY, 2012, 29 (03) : 1468 - 1476
  • [23] miR-21 inhibits the effects of cyclooxygenase-2 inhibitor NS398 on apoptosis and invasion in gastric cancer cells
    Li, Huanqing
    Cheng, Jian
    Mao, Yuqing
    Jiang, Miao
    Fan, Xiaoming
    ONCOTARGETS AND THERAPY, 2015, 8 : 3245 - 3253
  • [25] Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2
    Huang, Dong-Sheng
    Shen, Ke-Zhen
    Wei, Jian-Feng
    Liang, Ting-Bo
    Zheng, Shu-Sen
    Xie, Hai-Yang
    WORLD JOURNAL OF GASTROENTEROLOGY, 2005, 11 (02) : 204 - 207
  • [26] High Expression of COX-2 Associated with the Depth of Invasion on Acral Melanoma by Increasing TGF-β1
    Gipsyianti, Nastassa
    Aziz, Afiati
    Hernowo, Bethy S.
    Usman, Hermin A.
    CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2021, 14 : 209 - 216
  • [27] Differential synergistic anti-myeloma effects of the COX-2 inhibitor NS398, and bortezomib on doxorubicin-sensitive and resistant myeloma cells.
    Yang, HH
    Yan, XM
    Chen, HM
    Berenson, JR
    BLOOD, 2003, 102 (11) : 936A - 937A
  • [28] COX-2 Specific Inhibitor, NS-398, Increases Macrophage Migration Inhibitory Factor Expression and Induces Neuroendocrine Differentiation in C4-2b Prostate Cancer Cells
    Katherine Meyer-Siegler
    Molecular Medicine, 2001, 7 : 850 - 860
  • [29] COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4-2b prostate cancer cells
    Meyer-Siegler, K
    MOLECULAR MEDICINE, 2001, 7 (12) : 850 - 860
  • [30] Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398
    Bae, SH
    Jung, FS
    Park, YM
    Kim, BS
    Kim, BK
    Kim, DG
    Ryu, WS
    CLINICAL CANCER RESEARCH, 2001, 7 (05) : 1410 - 1418